Abstracts tagged "autoimmune diseases"

Abstract Number: 1747 • 2017 ACR/ARHP Annual Meeting
Human C-C Chemokine Receptor-6 (CCR6)+ Th Memory Cells, Including Th17 and Th17.1 Cells, Change into Anti-Inflammatory Cells with Regulatory Capacity upon Exposure to Vitamin D
Wendy Dankers¹, Nadine Davelaar², Jan Piet van Hamburg³, Patrick Asmawidjaja², Hoyan Wen², Johannes van Leeuwen⁴, Edgar Colin⁵ and Erik Lubberts², ¹Rheumatology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ²Rheumatology and Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ³Rheumatology, Erasmus MC, Rotterdam, Netherlands, ⁴Internal Medicine, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁵ZGT Almelo, Deventer, Netherlands
Background/Purpose: Autoimmune diseases such as RA are driven by an aberrantly activated immune system and an imbalance between pro- and anti-inflammatory cells, resulting in tissue…
Abstract Number: 184 • 2017 ACR/ARHP Annual Meeting
An Epigenome-Guided Approach to Causal Variant Discovery in Autoimmune Disease
Richard C. Pelikan¹, Jennifer A. Kelly², Yao Fu², Caleb Lareau³, Graham B. Wiley¹, Stuart Glenn¹, Martin Aryee^3,4, Courtney Montgomery⁵ and Patrick Gaffney², ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Department of Biostatistics, Harvard T.H. Chan School of Public Health, Charlestown, MA, ⁴Department of Pathology, Harvard Medical School, Boston, MA, ⁵Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Genome-wide association studies have identified thousands of genetic associations with complex human diseases and traits. However, establishing the truly causal regions of risk haplotypes…
Abstract Number: 1786 • 2017 ACR/ARHP Annual Meeting
Lupus Nephritis Is Linked to Immunity to an Intestinal Commensal Lachnospiracaea Species
Gregg J. Silverman¹, Doua F. Azzouz², Hanane El Bannoudi², Aidana Omarbekova³, Brad H. Rovin⁴, Roberto Caricchio⁵, Alexander Alekseyenko⁶ and Jill P. Buyon², ¹Department of Medicine, New York University School of Medicine, New York, NY, ²Medicine, New York University School of Medicine, New York, NY, ³New York University School of Medicine, New York, NY, ⁴Ohio State University Medical Center, Columbus, OH, ⁵Medicine/Rheumatology, Temple University, Philadelphia, PA, ⁶Medical University of South Carolina, Charleston, SC
Background/Purpose: A transmissible agent has long been suspected in the pathogenesis of SLE, yet the potential contribution of members of the intestinal microbiome to the…
Abstract Number: 210 • 2017 ACR/ARHP Annual Meeting
Pharmacovigilance Surveillance of Autoimmune Diseases Induced By Biological Agents: A Review of 12013 Cases (aeBIOGEAS-SEMI Registry)
Soledad Retamozo^1,2,3, Manuel Ramos-Casals^4,5, Marta Pérez de Lis⁶, Alejandra Flores-Chavez^7,8,9, Sofia Arteaga^10,11, Celeste Galcerán-Chaves¹², Belchin Kostov¹³, Roberto Pérez-Alvarez⁶ and Pilar Brito-Zerón^2,14, ¹Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Córdoba, Consejo Nacional de Investigaciones Científicas y Técnicas (INICSA-UNC-CONICET), Cordoba, Argentina, ²Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Barcelona, Spain, ³Rheumatology Unit, Hospital Privado Universitario de Córdoba, Institute University of Biomedical Sciences University of Córdoba (IUCBC), Cordoba, Argentina, ⁴Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ⁵Department of Medicine, University of Barcelona, Barcelona, Spain., Barcelona, Spain, ⁶Department of Internal Medicine, Hospital Alvaro Cunqueiro, Vigo, Vigo, Spain, ⁷Department of Autoimmune Diseases, ICMiD, Hospital Clínic Barcelona, Spain., Barcelona, Spain, ⁸Unidad de Investigación Biomédica 02 (Unidad de Investigación en Epidemiología Clínica), UMAE, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Jalisco, Mexico, ⁹Programa de Doctorado en Ciencias Médicas, Centro Universitario de Investigaciones Biomédicas (CUIB), Universidad de Colima, Colima, Mexico, Mexico, Mexico, ¹⁰Residente de Reumatologia II año, Universidad de Antioquia, Medellin, Colombia, Medellin, Colombia, ¹¹d) Department of Autoimmune Diseases, ICMiD, Hospital Clínic Barcelona, Spain., Barcelona, Spain, ¹²Neuroscience Clinical Institute, Hospital Clínic, Barcelona, Spain, Barcelona, Spain, ¹³Primary Care Research Group, IDIBAPS, Centre d’Assistència Primària ABS Les Corts, CAPSE, Barcelona, Barcelona, Spain, ¹⁴Autoimmune Diseases Unit, Department of Medicine, Hospital CIMA- Sanitas, Barcelona., Bacelona, Spain
Background/Purpose: The increasing use of biological agents has been linked with the paradoxical development of autoimmune processes. The scenario has dramatically change in recent years…
Abstract Number: 1792 • 2017 ACR/ARHP Annual Meeting
Distinct and Overlapping Activities of IL-17A and TNF on the Expression of Proinflammatory Cytokines and MMPs in Psoriatic Arthritis: Rationale for Anti-IL-17A/Anti-Tnfalpha Combination Therapy?
Xiaofei Xu¹, Nadine Davelaar², Anne-Marie Otten-Mus³, Patrick Asmawidjaja², J.M.W. Hazes⁴, Dominique Baeten⁵, Marijn Vis⁶, Radjesh Bisoendial¹ and Erik Lubberts², ¹Rheumatology, Erasmus MC, Rotterdam, Netherlands, ²Rheumatology and Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ³Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁴Department of Rheumatology, Erasmus University Medical Centre, Rotterdam, Netherlands, ⁵Clinical Immunology and Rheumatology/Experimental immunology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁶Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands
Background/Purpose: TNF and IL-17A are proinflammatory cytokines critically involved in the pathogenesis of psoriatic arthritis (PsA). Currently, targeting TNF is the first choice of a…
Abstract Number: 284 • 2017 ACR/ARHP Annual Meeting
Metabolic Activity Sustains Macrophage Cytokine Production in Rheumatoid Arthritis and Coronary Artery Disease
Cornelia M. Weyand¹, Markus Zeisbrich¹, Lukas Brosig², Barbara Wallis¹, Niall Roche³, Janice Lin¹ and Jorg Goronzy⁴, ¹Medicine: Immunology and Rheumatology, Stanford University, Stanford, CA, ²Medicine: Immunology and Rheumatology, Stanford University, Stanfod, CA, ³The Arthritis Center, Pleasanton, CA, ⁴Medicine/Division of Immunology & Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Accelerated atherosclerosis has become increasingly recognized as a complication of chronic inflammatory disease, such as in patients with rheumatoid arthritis (RA). RA patients have…
Abstract Number: 1999 • 2017 ACR/ARHP Annual Meeting
Magnetic Resonance Imaging of Skeletal Muscles in Patients with Dermatomyositis and Polymyositis: Novel and Distinctive Characteristic Findings
Taro Ukichi¹, Ken Yoshida¹, Satoshi Matsushima², Go Kawakami², Kentaro Noda¹, Kazuhiro Furuya¹ and Daitaro Kurosaka¹, ¹Division of Rheumatology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan, ²Department of Radiology, Jikei University School of Medicine, Tokyo, Japan
Background/Purpose: Radiological studies to distinguish between dermatomyositis (DM) and polymyositis (PM) are few. We predicted that the magnetic resonance imaging (MRI) findings of skeletal muscle…
Abstract Number: 900 • 2017 ACR/ARHP Annual Meeting
Choroid Plexus Tertiary Lymphoid Structures in Lupus: A Novel Neuro-Immune Interface
Ariel Stock¹, Evan Der², Sivan Gelb³, Ayal Ben-Zvi³ and Chaim Putterman⁴, ¹Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Hebrew University, Jerusalem, Israel, ⁴Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY
Background/Purpose: The central nervous system (CNS) manifestations of SLE remain poorly understood. Although potentially neuropathic autoantibodies have been identified in the serum, lupus patients show…
Abstract Number: 2111 • 2017 ACR/ARHP Annual Meeting
Anti-N-Methyl-D-Aspartate Receptor Encephalitis – Expanding Our Understanding of the Clinical Needs of Pediatric Patients with This Complex Disorder
Katherine A. Battisti¹, Tobias J. Tsai², Angela Pickersgill³ and Sheetal S. Vora⁴, ¹Emergency Medicine, Nationwide Children's Hospital, Columbus, OH, ²Physical Medicine and Rehabilitation, Levine Children's Hospital/Carolinas Medical Center, Charlotte, NC, ³Pediatrics, Levine Children's Hospital, Charlotte, NC, ⁴Pediatric Rheumatology, Levine Children's Hospital, Charlotte, NC
Background/Purpose: Although recognized only 10 years ago, anti-N-Methyl-D-Aspartate receptor encephalitis (anti-NMDAR encephalitis) has become a leading cause of encephalitis with an identifiable etiology in pediatric…
Abstract Number: 1002 • 2017 ACR/ARHP Annual Meeting
Survival and Years of Potential Life Lost in Connective Tissue Disease and Vasculitis; Data from the Norwegian Connective Tissue Diseases and Vasculitis Registry (NOSVAR)
Torhild Garen¹, Karoline Lerang¹, Anna Maria Hoffmann-Vold², Helena Andersson¹, Øyvind Midtvedt¹, Karin Kilian¹, Ragnar Gunnarsson¹, Birgir Gudbrandsson¹, Gudrun Norby¹, Oyvind Molberg² and Øyvind Palm¹, ¹Department of Rheumatology, Oslo University Hospital, Oslo, Norway, OSLO, Norway, ²Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway
Background/Purpose: Survival is decreased in patients with connective tissue diseases (CTDs) and vasculitis, however few studies have compared the mortality between the specific diseases prospectively…
Abstract Number: 2121 • 2017 ACR/ARHP Annual Meeting
Autoantibodies As Biomarkers for the Identification of Pre-Clinical Stages of Autoimmune Diseases: Demonstration of Inflammatory and Fibrotic Activity in the Liver of Asymptomatic and Biochemically Normal Individuals with Anti-Mitochondria Antibodies
Danielle Baldo¹, Alessandra Dellavance¹, Maria Lucia Ferraz² and Luis Eduardo C. Andrade^3,4, ¹Research and Development Department, Fleury Medicine and Health Laboratories, São Paulo, Brazil, ²Gastroenterology Division, Escola Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ³Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil, ⁴Immunology Division, Fleury Medicine and Health, São Paulo, Brazil
Background/Purpose: Circulating autoantibodies precede clinical onset of several autoimmune diseases. The characteristics of the so-called pre-clinical stage of autoimmune diseases are poorly understood. Anti-mitochondria autoantibodies…
Abstract Number: 1023 • 2017 ACR/ARHP Annual Meeting
The Autoimmune Discovery Ichip Distinguishes Healthy Individuals (HC) from Those with SLE, Rheumatoid Arthritis (RA), Scleroderma (SSc), Sjogren’s Syndrome (SS), and the Anti-Phospholipid Syndrome (APS)
Chaim Putterman¹, Armando Gabrielli², Alexandra Balbir-Gurman³, Pennina Safer⁴, Keren Jakobi-Brook⁴, Rachel Sorek⁴, Ilana Gluzman⁴, Steve Wallace⁵ and Irun R. Cohen^4,6, ¹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY, ²Istituto di Clinica Medica dell'Università di Ancona, Ancona, Italy, Ancona, Italy, ³Rheumatology Unit, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion, Haifa, Israel, Haifa, Israel, ⁴ImmunArray Ltd., Rehovot, Israel, Rehovot, Israel, ⁵ImmunArray Inc., VA, USA, Richmond, VA, ⁶Weizmann Institute of Science, Rehovot, Israel, Rehovot, Israel
Background/Purpose: Current serological tests are not sufficiently accurate in differentiating between HC and those with autoimmune rheumatic diseases. We developed the iCHIP antigen microarray to…
Abstract Number: 2128 • 2017 ACR/ARHP Annual Meeting
A Systematic Review of the Management of Patients with Preexisting Rheumatologic Diseases Receiving Checkpoint Inhibitors for Cancer
Noha Abdel-Wahab^1,2, Mohsin Shah¹, Maria A. Lopez-Olivo¹ and Maria Suarez-Almazor¹, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ²Rheumatology and Rehabilitation Department, Assiut University Hospitals, Assiut, Egypt, Assiut, Egypt
Background/Purpose: The incidence and management of rheumatologic immune-related adverse events (irAEs) as a consequence of the checkpoint inhibitor (CPI) therapy in patients with cancer has…
Abstract Number: 1064 • 2017 ACR/ARHP Annual Meeting
Characterization of Human Tolerogenic Dendritic Cells Generated with Protein Kinase C Inhibitor and Induction from Patients with Autoimmune Diseases
Hitoshi Hasegawa¹, Takuya Matsumoto¹, Endy Adnan², Jun Ishizaki¹, Koichiro Suemori¹ and Masaki Yasukawa¹, ¹Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan, ²Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan
Background/Purpose: Tolerogenic dendritic cells (tDCs) are a promising therapeutic tool for specific induction of immunological tolerance. Human tDCs can be generated ex vivo using various…
Abstract Number: 2142 • 2017 ACR/ARHP Annual Meeting
Autoantibodies Recognizing Cytosolic 5’-Nucleotidase 1A Are Associated with More Severe Disease in Patients with Juvenile Myositis
Richard Yeker¹, Iago Pinal-Fernandez², Takayuki Kishi³, Ira N. Targoff⁴, Frederick W Miller³, Lisa G Rider³ and Andrew Mammen⁵, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²NIAMS, NIH, Bethesda, MD, ³Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ⁴VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Muscle Diseases Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases. National Institutes of Health, Bethesda, MD
Background/Purpose: Autoantibodies recognizing cytosolic 5’-nucleotidase 1A (NT5C1A) are present in the sera of adults with myositis and other autoimmune diseases. They are especially prevalent in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.